General Information of the Disease (ID: M6ADIS0310)
Name
Silicosis
ICD
ICD-11: CA60
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 6 item(s) under this disease
Crosstalk ID: M6ACROT03225
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Lnc668
Epigenetic Regulator Histone acetyltransferase p300 (P300)
Regulated Target Histone H3 lysine 9 lactylation (H3K9la)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT03226
m6A Regulator YTH domain-containing protein 1 (YTHDC1)
m6A Target Lnc668
Epigenetic Regulator Histone acetyltransferase p300 (P300)
Regulated Target Histone H3 lysine 9 lactylation (H3K9la)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT03632
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Potassium voltage-gated channel subfamily H member 6 (KCNH6)
Epigenetic Regulator Histone acetyltransferase p300 (P300)
Regulated Target Histone H3 lysine 9 lactylation (H3K9la)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT03633
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Cadherin-1 (CDH1)
Epigenetic Regulator Histone acetyltransferase p300 (P300)
Regulated Target Histone H3 lysine 9 lactylation (H3K9la)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT05870
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Lnc668
Epigenetic Regulator Lnc668
Regulated Target Phosphatidylinositol-binding clathrin assembly protein (PICALM)
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05871
m6A Regulator YTH domain-containing protein 1 (YTHDC1)
m6A Target Lnc668
Epigenetic Regulator Lnc668
Regulated Target Phosphatidylinositol-binding clathrin assembly protein (PICALM)
Crosstalk relationship m6A → ncRNA
References
Ref 1 Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. doi: 10.1007/s11095-004-1871-1.
Ref 2 A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43. doi: 10.1158/1535-7163.MCT-05-0313.